Daihan Pharmaceutical Co.,Ltd.

KOSDAQ:A023910 Stock Report

Market Cap: ₩152.9b

Daihan PharmaceuticalLtd Future Growth

Future criteria checks 0/6

Daihan PharmaceuticalLtd is forecast to grow earnings and revenue by 0.9% and 3.6% per annum respectively. EPS is expected to grow by 0.5% per annum. Return on equity is forecast to be 10.2% in 3 years.

Key information

0.9%

Earnings growth rate

0.5%

EPS growth rate

Pharmaceuticals earnings growth33.4%
Revenue growth rate3.6%
Future return on equity10.2%
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

Mar 02
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Feb 09
Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

Jan 19
Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Dec 18
What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

Nov 27
Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

KOSDAQ:A023910 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026214,80031,55019,30042,3002
12/31/2025207,20030,35017,10040,2002
12/31/2024202,70031,10015,90037,1001
9/30/2024201,97430,66515,59437,009N/A
6/30/2024198,05230,03612,55136,320N/A
3/31/2024198,83429,38413,84638,316N/A
12/31/2023195,91128,42617,58038,860N/A
9/30/2023194,52826,21124,14639,159N/A
6/30/2023192,25926,52123,15935,516N/A
3/31/2023189,04326,08924,76133,110N/A
12/31/2022184,26824,96120,37828,999N/A
9/30/2022181,12226,19720,73929,322N/A
6/30/2022177,12625,02921,55029,953N/A
3/31/2022173,72623,69025,40936,413N/A
12/31/2021171,46322,67028,76740,617N/A
9/30/2021166,61916,68026,57636,612N/A
6/30/2021165,49516,16623,43332,278N/A
3/31/2021162,37215,56823,10729,355N/A
12/31/2020166,08017,38128,26733,627N/A
9/30/2020170,11626,24620,90532,312N/A
6/30/2020170,01126,43828,29140,193N/A
3/31/2020172,49228,70222,20138,203N/A
12/31/2019168,76228,16717,95935,264N/A
9/30/2019165,17827,40826,35139,995N/A
6/30/2019161,92627,61824,25539,859N/A
3/31/2019158,29828,256-1,72343,297N/A
12/31/2018158,72028,518-1,74844,944N/A
9/30/2018153,40226,631-11,21044,796N/A
6/30/2018152,13027,449N/A38,153N/A
3/31/2018149,08326,148N/A30,615N/A
12/31/2017144,43924,832N/A20,455N/A
9/30/2017145,31923,702N/A17,452N/A
6/30/2017140,74321,183N/A19,191N/A
3/31/2017140,07718,881N/A22,031N/A
12/31/2016139,43717,657N/A27,924N/A
9/30/2016134,84316,853N/A23,294N/A
6/30/2016131,99415,774N/A21,432N/A
3/31/2016128,84515,285N/A20,744N/A
12/31/2015124,27613,776N/A17,975N/A
9/30/2015121,29612,275N/A15,661N/A
6/30/2015118,69811,126N/A14,635N/A
3/31/2015114,7399,817N/A10,230N/A
12/31/2014111,70910,420N/A9,483N/A
9/30/2014109,61010,000N/A13,633N/A
6/30/2014107,8347,924N/A10,318N/A
3/31/2014107,2298,305N/A13,680N/A
12/31/2013106,8037,771N/A12,686N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A023910's forecast earnings growth (0.9% per year) is below the savings rate (2.7%).

Earnings vs Market: A023910's earnings (0.9% per year) are forecast to grow slower than the KR market (28% per year).

High Growth Earnings: A023910's earnings are forecast to grow, but not significantly.

Revenue vs Market: A023910's revenue (3.6% per year) is forecast to grow slower than the KR market (9.3% per year).

High Growth Revenue: A023910's revenue (3.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A023910's Return on Equity is forecast to be low in 3 years time (10.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y